Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Recommendation of “Buy” by Brokerages

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWNGet Rating) has been assigned a consensus recommendation of “Buy” from the six research firms that are covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $39.00.

Several equities research analysts recently commented on DAWN shares. HC Wainwright started coverage on Day One Biopharmaceuticals in a report on Thursday, December 15th. They issued a “buy” rating and a $35.00 price target for the company. Needham & Company LLC started coverage on Day One Biopharmaceuticals in a report on Wednesday, December 14th. They issued a “buy” rating and a $40.00 price target for the company. The Goldman Sachs Group started coverage on Day One Biopharmaceuticals in a report on Monday, December 5th. They issued a “buy” rating and a $45.00 price target for the company. Piper Sandler increased their price target on Day One Biopharmaceuticals from $40.00 to $45.00 in a report on Sunday. Finally, Bank of America assumed coverage on Day One Biopharmaceuticals in a report on Thursday, December 1st. They issued a “buy” rating and a $34.00 price target for the company.

Day One Biopharmaceuticals Stock Performance

NASDAQ DAWN opened at $21.34 on Monday. The stock’s 50 day simple moving average is $20.73 and its 200-day simple moving average is $20.76. Day One Biopharmaceuticals has a 1-year low of $5.44 and a 1-year high of $28.35.

Day One Biopharmaceuticals (NASDAQ:DAWNGet Rating) last released its earnings results on Monday, November 7th. The company reported ($0.53) earnings per share for the quarter, meeting the consensus estimate of ($0.53). As a group, sell-side analysts forecast that Day One Biopharmaceuticals will post -2.18 EPS for the current year.

Insiders Place Their Bets

In other news, Director Julie Papanek Grant sold 25,000 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, January 3rd. The stock was sold at an average price of $20.65, for a total value of $516,250.00. Following the completion of the sale, the director now directly owns 380,000 shares of the company’s stock, valued at $7,847,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, CEO Jeremy Bender sold 12,500 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, November 1st. The stock was sold at an average price of $20.03, for a total value of $250,375.00. Following the completion of the sale, the chief executive officer now directly owns 1,215,375 shares of the company’s stock, valued at $24,343,961.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Julie Papanek Grant sold 25,000 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $20.65, for a total value of $516,250.00. Following the completion of the sale, the director now directly owns 380,000 shares of the company’s stock, valued at $7,847,000. The disclosure for this sale can be found here. Insiders sold a total of 119,178 shares of company stock valued at $2,458,187 over the last quarter. 8.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp boosted its holdings in Day One Biopharmaceuticals by 60.9% in the third quarter. Bank of New York Mellon Corp now owns 102,223 shares of the company’s stock valued at $2,048,000 after purchasing an additional 38,681 shares during the period. California State Teachers Retirement System lifted its holdings in Day One Biopharmaceuticals by 9.5% during the 3rd quarter. California State Teachers Retirement System now owns 10,929 shares of the company’s stock worth $219,000 after buying an additional 944 shares during the last quarter. State Street Corp lifted its holdings in Day One Biopharmaceuticals by 469.1% during the 3rd quarter. State Street Corp now owns 2,041,738 shares of the company’s stock worth $40,896,000 after buying an additional 1,682,955 shares during the last quarter. Tang Capital Management LLC purchased a new stake in Day One Biopharmaceuticals during the 3rd quarter worth about $8,012,000. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Day One Biopharmaceuticals by 2.6% during the 3rd quarter. Price T Rowe Associates Inc. MD now owns 2,094,913 shares of the company’s stock worth $41,962,000 after buying an additional 53,569 shares during the last quarter. 86.08% of the stock is currently owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals Company Profile

(Get Rating)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.

Featured Articles

Analyst Recommendations for Day One Biopharmaceuticals (NASDAQ:DAWN)

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.